Xeris Biopharma Holdings

ISIN US98422E1038

 | 

WKN A3C4ZC

Market cap (in EUR)
823 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overzicht

Beschrijving

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Toon meer Toon minder
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR 823 m
WPA, EUR -0.01
KBV 66.3
K/W 1,706.2
Dividendrendement 0.00%

Income statement (2025)

Omzet, EUR 259 m
Netto-inkomen, EUR 0 m
Winstmarge 0.19%

What ETF is Xeris Biopharma Holdings in?

There is 1 ETF which contains Xeris Biopharma Holdings.
ETF Weging Investeringsfocus Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.09%
Equity
United States
Health Care
Biotech
47
— Les données utilisées sont mises à disposition par Trackinsight, etfinfo, Xignite Inc., gettex, FactSet et justETF GmbH.

Les cotations sont des cotations en temps réel (gettex), des cotations boursières retardées de 15 minutes ou des VNI (quotidiennes publiées par le fournisseur du fonds). Par défaut, les rendements des ETF incluent les paiements de dividendes (le cas échéant). Aucune garantie n'est donnée quant à l'exhaustivité, la précision et l'exactitude des informations affichées.